Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kiadis Pharma, a biopharmaceutical company, has announced that the FDA has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma.
Subscribe to our email newsletter
One orphan drug designation has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
The FDA’s orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the US. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product approval.
Manja Bouman, CEO of Kiadis Pharma, said: “This is an important strategic milestone in the development of Reviroc and we are very pleased with the orphan drug designations received from the FDA.”